In the first quarter of 2025, the total import and export value of health products by China Meheco Group reached 47.088 billion USD, with a slight increase of 0.38% year-on-year.

In the first quarter of 2025, the import and export trade of health care products from China Meheco Group showed characteristics of "stable total volume and optimized structure" amidst a complex and changing international environment.

Zhitong FinanceMay 13 04:40 ET

China Securities Co.,Ltd.: The China Meheco Group Industry needs to accelerate its international layout, and is bullish on the trend of self-controlled Medical Device going abroad.

Based on the internal, expand externally.

Zhitong FinanceMay 12 19:32 ET

Express News | China Meheco Says It Plans to Buy 100% Stake in Technology Company for 302.1 Mln Yuan

ReutersMay 12 07:25 ET

Meheco's Unit Gets European Union's Nod to Market Troxerutin Raw Drug Ingredient

MT NewswiresMay 2 04:34 ET

China Pharmaceuticals: Report for the first quarter of 2025

SZSIApr 29 12:00 ET · Announcements

2025 First Quarter Report

SZSIApr 29 12:00 ET · Announcements

In the first quarter, China Meheco Group (600056.SH) reported a net income of 0.166 billion yuan, an increase of 14.27% year-on-year.

On April 29, Gelonghui reported that China Meheco Group (600056.SH) released its first quarter report, achieving a total operating income of 8.263 billion yuan in Q1 2025, a year-on-year decrease of 5.84%; the net income attributable to shareholders of the parent company was 0.166 billion yuan, an increase of 14.27% year-on-year; the basic EPS was 0.1112 yuan.

Gelonghui FinanceApr 29 08:45 ET

2024 Annual Report Summary

SZSIApr 25 12:00 ET · Announcements

Full 2024 Annual Report

SZSIApr 25 12:00 ET · Announcements

TRAD CHI MED has received a Shareholding increase of 50.35 million shares from its controlling Shareholder, China National Pharmaceutical Group.

TRAD CHI MED (00570) announced that the company's Board of Directors received a notice from the company's controlling shareholder, China Meheco Group (China National Pharmaceutical Group), indicating that, based on confidence in the company's continued and stable development, China Meheco Group directly increased its Shareholding by 50.35 million shares at an average price of approximately HKD 1.86 per share from the open market on April 8, 2025. As of the date of this announcement, China Meheco Group directly and indirectly holds 1.685 billion shares of the company (prior to Shareholding increase: 1.635 billion shares), accounting for approximately 33.46% of all issued shares of the company (prior to Shareholding increase: approximately 32.46%).

Sina Hong Kong stocksApr 8 20:52 ET

Is China Meheco Group Co., Ltd.'s (SHSE:600056) Recent Price Movement Underpinned By Its Weak Fundamentals?

Simply Wall StApr 7 18:33 ET

Brokerage morning meeting highlights: The USA has increased tariffs on China, but the impact on these industries in the A-shares may be limited.

In today's brokerage morning meeting, GF SEC believes that the USA's tariffs on China have a limited impact on the A-share Computer Industry; China Securities Co.,Ltd. suggested being Bullish on the Innovative Drugs industry that is currently not affected by tariffs; Galaxy Securities stated that Deep Sea Technology has entered a new stage in Global Strategy, focusing on opportunities in core equipment.

cls.cnApr 6 20:17 ET

China Meheco Group (600056.SH): The subsidiary has received the approval notice for the listing application of Chemical Raw Materials.

Gelonghui reported on March 24 that China Meheco Group (600056.SH) announced that its wholly-owned subsidiary Tianfang Pharmaceutical Co., Ltd. (referred to as "Tianfang Pharmaceutical") has received a notification of approval for the marketing application of Febuxostat Chemical Raw Materials issued by the National Medical Products Administration. This pharmaceutical is suitable for the treatment of hyperuricemia in patients with gout. The approval of the marketing application for Febuxostat Chemical Raw Materials by Tianfang Pharmaceutical indicates that this Active Pharmaceutical Ingredient meets the relevant regulatory requirements for domestic drug registration and has been approved for use in domestic formulations. On one hand, it will achieve autonomous control of the company's Active Pharmaceutical Ingredient, and on the other hand, it indicates that this product can be.

Gelonghui FinanceMar 24 04:04 ET

Meheco Unit's Tranexamic Acid Injection Passes Regulatory Evaluation

MT NewswiresMar 10 23:24 ET

China Meheco Group (600056.SH): Tranexamic Acid Injection has passed the consistency evaluation for generic drugs.

On March 10, Gelonghui reported that China Meheco Group (600056.SH) announced that its wholly-owned subsidiary Tianfang Pharmaceutical Co., Ltd. had received an approval notice from the National Medical Products Administration for a supplementary application for tranexamic acid injection, which has passed the consistency evaluation of the quality and efficacy of generic drugs. Tranexamic acid injection is mainly used for various bleeding caused by acute or chronic, localized or systemic primary hyperfibrinolysis, which was originally developed by Daiichi Sankyo Company, Limited in Japan and was approved for market in Japan in 1965.

Gelonghui FinanceMar 10 05:22 ET

Meheco's Unit Gets Nod to Market Sacubitril-Valsartan Sodium Tablets

MT NewswiresMar 4 00:01 ET

The amount involved exceeds 0.5 billion yuan and the equity transfer dispute of China Meheco Group is still ongoing | Quick read of the announcement.

① China Meheco Group has appealed to the court regarding the acquisition of the remaining 30% equity in Jinlun Pharmaceutical (now named Hebei Tongyong) held by Wang Yibing; ② The amount involved in this lawsuit reaches 0.51 billion yuan.

cls.cnFeb 28 10:46 ET

[Brokerage Focus] CMB International indicates that China Meheco Group has started a valuation recovery.

Jinwu Financial News | China Merchants International states that the MSCI Chinese Medical Index has risen 5.3% year-to-date as of early 2025, outperforming the MSCI Chinese Index by 0.9%. Benefiting from overseas interest rate cuts and improvements in the domestic macro environment, the pharmaceutical sector, as a highly elastic industry, is expected to outperform the market in 2025. The Category C medical insurance directory is set to be implemented within the year, and Innovative Drugs will benefit from better payment conditions through commercial health insurance coverage. The bidding for Medical Devices is accelerating its recovery, which will drive the profit recovery of domestic medical device companies. The bank is Bullish about the recovery of industry valuations. It recommends buying WUXI APPTEC (02359, 603259 CH).

King Wu Financial NewsFeb 10 01:45 ET

Zhaoyin International: Bullish on the valuation repair of the China Meheco Group Industry, recommending to Buy WUXI APPTEC (02359) and others.

Cinda International believes that China will become a necessary place for overseas pharmaceutical companies to seek innovative drug pipelines, and innovative drugs from China will play an increasingly important role on the international stage.

Zhitong FinanceFeb 9 20:46 ET

China Meheco Group (SHSE:600056) Shareholders Notch a 14% CAGR Over 3 Years, yet Earnings Have Been Shrinking

Simply Wall StFeb 7 21:24 ET